- Home
- LSH vs APLM Comparison
LSH vs APLM Comparison
Compare LSH & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- APLM
- Stock Information
- Founded
- LSH 2018
- APLM 2016
- Country
- LSH United States
- APLM United States
- Employees
- LSH N/A
- APLM N/A
- Industry
- LSH
- APLM Blank Checks
- Sector
- LSH
- APLM Finance
- Exchange
- LSH NYSE
- APLM Nasdaq
- Market Cap
- LSH 7.3M
- APLM 6.9M
- IPO Year
- LSH 2024
- APLM N/A
- Fundamental
- Price
- LSH $0.93
- APLM $6.50
- Analyst Decision
- LSH
- APLM
- Analyst Count
- LSH 0
- APLM 0
- Target Price
- LSH N/A
- APLM N/A
- AVG Volume (30 Days)
- LSH 47.7K
- APLM 9.8K
- Earning Date
- LSH 08-01-2025
- APLM 04-03-2025
- Dividend Yield
- LSH N/A
- APLM N/A
- EPS Growth
- LSH N/A
- APLM N/A
- EPS
- LSH N/A
- APLM N/A
- Revenue
- LSH $16,270,095.00
- APLM $198,000.00
- Revenue This Year
- LSH N/A
- APLM $415.15
- Revenue Next Year
- LSH N/A
- APLM N/A
- P/E Ratio
- LSH N/A
- APLM N/A
- Revenue Growth
- LSH N/A
- APLM N/A
- 52 Week Low
- LSH $0.84
- APLM $4.47
- 52 Week High
- LSH $5.37
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- APLM 53.81
- Support Level
- LSH N/A
- APLM $5.96
- Resistance Level
- LSH N/A
- APLM $7.39
- Average True Range (ATR)
- LSH 0.00
- APLM 0.77
- MACD
- LSH 0.00
- APLM 0.08
- Stochastic Oscillator
- LSH 0.00
- APLM 54.43
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.